Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy

Expert Opinion on Orphan Drugs

Volumn 1, Issue 1, 2013, Pages 33-46

  Scully, Michele A ^a   Pandya, Shree ^a   Moxley, Richard T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Corticosteroids; Duchenne muscular dystrophy; Therapeutics

Indexed keywords

ATALUREN; CORTICOSTEROID; DEFLAZACORT; DRISAPERSEN; DYSTROPHIN; ETEPLIRSEN; GENTAMICIN; MYOSTATIN INHIBITOR; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; PROTEIN INHIBITOR; RAMATERCEPT; SILDENAFIL; SOMATOMEDIN C; TADALAFIL; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EVIDENCE BASED PRACTICE; EXON SKIPPING; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; LONG TERM CARE; NONHUMAN; NUTRITIONAL DEFICIENCY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STOP CODON;

EID: 84896705346     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.746939     Document Type: Review

References (117)

1. Hoffman EP. Dystrophinopathies. In: Karpati G, Hilton-Jones D, Griggs R, editors. Disorders of voluntary muscle. Cambridge University Press; Cambridge: 385-432
2. Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009;155(3):380-5
3. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disord 2002;12(10):926-9
4. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64(1):13-20
5. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008(1):CD003725
6. Griggs RC, Moxley RT III, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43(3 Pt 1):520-7
7. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind sixmonth trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320(24):1592-7
8. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41(12):1874-47
9. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48(4):383-8
10. Bonifati DM, Ruzza G, Bonometto P, et al. A multicenter double-blind randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23(9):1344-7
11. Mesa LE, Dubrosvky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscular Disord 1991;1(4):261-6
12. Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: a study of long-term effect. Muscle Nerve 1994;17(4):386-91
13. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84(11):843-50
14. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16(4):249-55
15. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68(19):1607-13
16. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow up. Pediatr Neurol 2008;38(3):200-6
17. Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14 year follow-up. Muscle Nerve 2012;45(6):796-802
18. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial mangement. Lancet Neurol 2010;9(1):77-93
19. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lance Neurol 2010;9(2):177-89
20. Moxley RT III, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25(9):1116-29
21. McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica 2012;31(1):16-20
22. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet 1993;3(4):283-91
23. Aartsma-rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006;34(2):135-44
24. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2(1):90-5
25. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45(4):498-506
26. England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990;343(6254):180-2
27. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4(8):1251-8
28. Deburgrave N, Daoud F, Liense S, et al. Protein- and mRNA-based phenotypegenotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007;28(2):183-95
29. Kirschner J, Schessl J, Schara U, et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010;9(11):1053-9
30. Drachman DB, Tokya KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2(7894):1409-12
31. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77(5):444-52
32. Robert G. Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD). In: clinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT01603407?term= NCT01603407&rank=1: NCT01603407
33. Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increase sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83(1):144-51
34. Reeves EK, Rayavarapu S, Damsker JM, Nagaraju K. Glucocorticoid anlogues: potential therapeutic alternatives for treating inflammatory muscle diseases. Endocr Metab Immune Disord Drug Targets 2012;12(1):95-103
35. Bonifati DM, Witchel SF, Ermani M, et al. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry 2006;77(10):1177-9
36. De Bosscher K, Beck IM, Haegeman G. Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system? Bran Behav Immun 2010;7):1035-42
37. Bello L, Piva L, Barp A, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 2012;79(2):159-62
38. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387(6628):83-90
39. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94(23):12457-61
40. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63(5):561-71
41. Bish LT, Sleeper MM, Forbes SC, et al. Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther 2011;22(12):1499-509
42. Schneyer AL, Sidis Y, Gulati A, et al. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 2008;149(9):4589-95
43. Nakatani M, Tekehara Y, Sugino H, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 2008;22(2):477-87
44. Benabdallah BF, Bouchentouf M, Rousseau J, et al. Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant 2008;17(3):337-50
45. Jerry RM. Follistatin gene transfer to patients with becker muscular dystrophy and sporadic inclusion body myositis. In: clinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT01519349?term=NCT01519349& rank=1: NCT01519349
46. Cadena SM, Tomkinson KN, Monell TE, et al. Administration of soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010;109(3):635-42
47. Acceleron Pharma, Inc. A safety, tolerability, pharmacokinetic and pharmacodynamic study of ACE-031 in healthy postmenopausal women. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); Available from: http:// clinicaltrials.gov/ct2/show/ NCT00952887?term=ace-031&rank=1: NCT00952887
48. Acceleron Pharma, Inc. Study of ACE-031 in subjects with Duchenne muscular dystrophy. In: ClinicalTrials. gov [Internet] National Library of Medicine (US), Bethesda (MD); 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01099761?term=ace- 031&rank=3 NCT01099761
49. Lee KH, Baek MY, Moon KY, et al. Nitric oxide as a messenger molecule for myoblast fusion. J Biol Chem 1994;269(20):14371-4
50. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82(5):743-52
51. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol 2001;155(1):123-31
52. Chang WJ, Iannaccone ST, Lau KS, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA 1996;93(17):9142-7
53. Sander MB, Chavoshan B, Harris SA, et al. Functional muscle ischemia in neuronal nitric oxide synthase deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2000;97(25):13818-23
54. Percival JM, Whitehead NP, Adams ME, et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012;228(1):77-87
55. Ron V. Tadalafil and sildenafil for duchenne muscular dystrophy. In: clinicaltrials.gov [Internet] National Library of Medicine (US), Bethesda (MD): 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01359670? term=sildenafil+duchenne&rank=2: NCT0135970
56. Escolar DM, Zimmerman A, Bertorini T, et al. Pentoxifylline as a rescue treatment for DMD. A randomized double-blind clinical trial. Neurology 2012;78(12):904-13
57. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000;10(4-5):235-9
58. Jorgensen JO, Moller L, Krag M, et al. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 2007;36(1):75-87
59. Schertzer JD, van der Poel C, Shavlakadze T, et al. Muscle-specific over expression of IGF-1 improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 2008;294(1):C161-8
60. Ampong BN, Imamura M, Matsumiya T, et al. Intracellular localization of dysferlin and its association with the dihydropyridine receptor. Acta Myol 2005;24(2):134-44
61. Rosenthal SM, Cheng ZQ. Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal muscle. Proc Natl Acad Sci USA 1995;92(22):10307-10311
62. Engert JC, Berglund EB, Rosenthal N. Proliferation precedes differentiation in IGF-1-stimulated myogenesis. J Cell Biol 1996;135(2):431-40
63. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27(2):195-200
64. Barton-Davis ER, Shorturma DI, Musaro A, et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998;95(26):15603-7
65. Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002;157(1):137-48
66. Gregorevic P, Plant DR, Leeding KS, et al. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002;1(6):2263-72
67. Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther 2005;12(3):441-50
68. Sacca F, Quarantelli M, Rinaldi C, et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. J Neurol 2012;259(1):132-8
69. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71(22):1770-5
70. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 1998;51(2):583-6
71. Heatwole CR, Eichinger KJ, Friedman DI, et al. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol 2011;68(1):37-44
72. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, et al. Metabolic and clinical response to recombinant human insulin-like growth factor 1 in myotonic dystrophy. J Clin Endocrinol Metab 1995;80(12):3715-23
73. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo controlled study. The North America ALS/IGF-1 Study Group. Neurology 1997;49(6):1621-30
74. Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92(7):2480-6
75. Weissberger AJ, Anastasiadis AD, Strugess I, et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clin Endocrinol 2003;58(1):99-107
76. Rao MN, Mulligan K, Tai V, et al. Effects of insulin-like growth factor (IGF)-1/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010;95(9):4361-6
77. Children's Hospital Medical Center, Cincinnati. Safety and efficacy study of IGF-1 in duchenne muscular dystrophy. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01207908?term=IGF- 1+duchenne&rank=1: NCT01207908
78. Novak F, Heyland DK, Avenell A, et al. Glutamine supplementation in serious illness: a systemic review of the evidence. Crit Care Med 2002;30(9):2022-9
79. Hankard RG, Hammond D, Haymond MW, Darmaun D. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res 1998;43(2):222-6
80. Hankard R, Mauras N, Hammond D, et al. Is glutamine a 'conditionally essential' amino acid in Duchenne muscular dystrophy? Clin Nutr 1999;18(6):365-9
81. Mok E, Letellier G, Cuisset JM, et al. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial. PLoS ONE 2009;4(5):e5448
82. Mendell JR, Griggs RC, Moxley RT III, et al. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine. Muscle Nerve 1984;7(7):535-41
83. Payne ET, Yasuda N, Bourgeois JM, et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 2006;33(1):66-77
84. Passaquin AC, Renard M, Kay L, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002;12(2):174-82
85. Pulido SM, Passaquin AC, Leijendekker WJ, et al. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 1998;493(3):357-62
86. Tarnopolsky MA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004;62(10):1771-7
87. Banerjee B, Sharma U, Balasubramanian K, et al. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized. placebo-controlled 31P MRS Study. Magn Reson Imaging 2010;28(5):698-707
88. Anderson WF, Gorini L, Breckenridge L. Role of ribosomes in streptomycin-activated suppression. Proc Natl Acad Sci USA 1965;54(4):1076-83
89. Davies J, Gilbert W, Gorini L. Streptomycin, suppression, and the code. Proc Natl Acad Sci USA 1964;51:883-90
90. Barton-Davis ER, Cordier L, Shotuma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104(4):375-81
91. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49(6):706-11
92. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003;22(1):15-21
93. Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67(6):771-80
94. Ghahramani Seno MM, Graham IR, Athanasopoulous T, et al. RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Hum Mol Genet 2008;17:2622-32
95. Nudelman I, Rebibo-Sabbah A, Cherniavsky M. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009;52(9):2836-45
96. Lee HL, Dougherty JP. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 2012;136(2):227-66
97. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
98. PTC Therapeutics. Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystorphy (DMD/BMD). In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2011. Available from: http://clinicaltrials.gov/ct2/show/ NCT00592553?term=NCT00592553& rank=1: NCT00592553
99. PTC Therapeutics. Study of Ataluren for Previously Treated Patients With nmDBMD in the US. In: ClinicalTrials. gov [Internet] National Library of Medicine (US), Bethesda (MD); 2011.Available from: http://clinicaltrials. gov/ct2/show/NCT01247207? term=NCT01247207&rank=1: NCT01247207
100. Aartsma-Rus A, Janson AA, Kaman WE, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003;12:907-14
101. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 2009;65:667-76
102. Van Deutekom JC, Janson AA, Ginjaar LB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357(26):2677-86
103. Goemans NM, Tullinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364(16):1513-22
104. GlaxoSmithKline. A clinical study to assess the efficacy and safety of GSK2402968 in Subjects with Duchenne Muscular Dystrophy (DMD114044). In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT01254019?term=NCT01254019& rank=1 NCT01254019
105. Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012;20(2):462-7
106. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378(9791):595-605
107. Sarepta Therapeutics. Full 48-week Phase IIb data from eteplirsen study in Duchenne presented at World Muscle Society. [October 16, 2012]. Retrieved on October 26 Availble from http://issuu.com/ parentprojectmd/docs/mendell- eteplirsen-48-week-data-wms2012-final
108. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134(Pt 12):3547-59
109. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50(3):509-17
110. Scott JM, Li S, Harper SQ, et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 2002(Suppl 1):S23-9
111. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2000;97(25):13614-719
112. Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 2010;18(8):1501-18
113. Zhang Y, Duan D. Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther 2012;23(1):98-103
114. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin Immunity in Duchenne's Muscular Dystrophy. N Eng J Med 2010;363(15):1429-37
115. Florence J, Connolly A, Miller JP, et al. Outcomes measure reliabiliity in non ambulatory boys and men with Duchenne Muscular Dystrophy (DMD): Results from the Muscular Dystrophy Association DMD clinical research network. Neurology 2012;78(Meeting Abstracts 1):P04.085
116. Lowes L, Alfano L, Viollet L, et al. Moderate walking distances and velocity correlate with function comparable to 6 minute walk test. Neurology 2012;78(Meeting Abstracts 1):S49.005
117. Connolly A, Florence J, Cradock M, et al. Motor and cognitive assessment of infants and young boys with duchenne muscular dystrophy; results from the muscular dystrophy association dmd clinical research center network. Neurology 2012;78(Meeting Abstracts 1):P04.084